News & Events

ASH Joint Program Committees have selected LP-168 preclinical and clinical abstracts for oral presentations at the 65th ASH Annual Meeting and Exposition, December 9-12, 2023, in San Diego, California. LP-168 is a novel next generation BTK inhibitor invented by Guangzhou Lupeng Pharmaceutical Co., Ltd.. Abstracts are available on the ASH website.

Wednesday, January 12, 2022 (EST), Lupeng Pharmaceuticals presented at the 40th Annual J.P. Morgan Healthcare Conference. Dr. Stephen Anthony, the CMO of US/EU/UK Oncology Operation, gave a presentation on behalf of the company. Dr. Anthony shared the fast-growth of Lupeng in the past few years, including the key milestones achieved in several projects and the development of an innovative anti-cancer pipeline, which attracted the attention of many domestic and international companies.

December 13, 2021: 2:45 PM (EST), Lupeng Pharmaceutical presented the latest data of its own proprietary LP-118, the next generation of Bcl-2 inhibitor, at the 63rd American Society of Hematology (ASH) Annual Meeting. The title is "Characterization of LP-118, a Novel Small Molecule Inhibitor of Bcl-2 and Bcl-Xl in Chronic Lymphocytic Leukemia Resistant to Venetoclax (Abstract Number: 679)". Dr. Jennifer A. Woyach of Ohio State University, Dr. Deepa Sampath of the University of Texas MD Anderson Cancer Center, and Dr John C. Byrd of University of Cincinnati were the principal investigator of this oral presentation.